On March 20, 2026, Mainz Biomed N.V. received a notification from the Nasdaq Stock Market indicating that the company did not meet the minimum bid price requirement of $1.00 per share for continued listing. This determination was based on the closing bid price of the company's ordinary shares over a 30-day period from February 5, 2026, to March 19, 2026. The company has been granted a compliance period of 180 calendar days, expiring on September 16, 2026, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To meet this requirement, Mainz Biomed's ordinary shares must maintain a minimum closing bid price of $1.00 for at least ten consecutive business days during the compliance period. If the company fails to regain compliance by the end of this period, it may be eligible for an additional compliance period, provided it meets other listing requirements. However, there is no guarantee that the company will qualify for this extension or that Nasdaq will grant its request for continued listing. The notification does not have an immediate impact on the trading of the company's shares, which will continue to be listed on Nasdaq, pending compliance with other listing requirements.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.